Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

被引:0
|
作者
Li, Qingsong [1 ,2 ,3 ]
Liang, Na [1 ,2 ,3 ]
Ouyang, Weiwei [1 ,2 ,3 ]
Su, Shengfa [1 ,2 ,3 ]
Ma, Zhu [1 ,2 ]
Geng, Yichao [1 ,2 ,3 ]
Hu, Yinxiang [1 ,2 ,3 ]
Li, Huiqin [1 ,2 ]
Lu, Bing [1 ,2 ,3 ]
机构
[1] Guizhou Med Univ, Affiliated Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[3] Guizhou Med Univ, Clin Med Coll, Teaching & Res Dept Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
关键词
Time; Non-small cell lung cancer (NSCLC); EGFR-TKIs; Primary tumor radiotherapy; Overall survival; TYROSINE KINASE INHIBITORS; OPEN-LABEL; PHASE-III; ADENOCARCINOMA HISTOLOGY; CONCURRENT CHEMOTHERAPY; MAINTENANCE THERAPY; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; RADIATION-THERAPY; GEFITINIB;
D O I
10.1186/s12885-024-12826-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research. Patients and methods In total, 238 patients with EGFR-TKIs and OS >= 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it. The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R0 - 30(<30 days), R30 - PD(>= 30 days and disease stable), and R-PD(radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated. Results The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3-33.7) for the R group and 22 months(95% CI: 20.4-23.6) for the D group (chi(2) = 13.480, p<0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS. Among the four groups, The R30 - PD appeared to have the best OS (D, chi(2) = 19.307, p<0.001;R0 - 30, chi(2) = 11.687, p = 0.01; R-PD, chi(2) = 4.086, p = 0.043). Landmark analyses(22 months) showed the R30 - PD group had a significant long-term OS. The incidence of radiation pneumonitis >= grade 2 was17.3%(n = 19)and radiation esophagitis >= grade 2 was observed in 32 patients(29.1%). Conclusions Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 - PD)of primary tumour radiotherapy may be the best choice. Premature radiotherapy(R0 - 30) and radiotherapy after disease progression (R-PD)may not be reasonable for long-term OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
    Zhang, Jian-Wei
    Zhao, Yuan-Yuan
    Guo, Ying
    Xue, Cong
    Hu, Zhi-Huang
    Huang, Yan
    Zhao, Hong-Yun
    Zhang, Jing
    Wu, Xuan
    Fang, Wen-Feng
    Ma, Yu-Xiang
    Zhang, Li
    CHINESE JOURNAL OF CANCER, 2014, 33 (02) : 105 - 114
  • [2] The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
    Yu, Xiaoqing
    Si, Jinfei
    Wei, Jingwen
    Wang, Yanling
    Sun, Yan
    Jin, Jianan
    Zhang, Xiaoyan
    Ma, Tonghui
    Song, Zhengbo
    CANCER MEDICINE, 2023, 12 (05): : 5630 - 5638
  • [3] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [4] Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in Bone Lesions for Non-small Cell Lung Cancer
    Inomata, Minehiko
    Shukuya, Takehito
    Takahashi, Toshiaki
    Ono, Akira
    Nakamura, Yukiko
    Tsuya, Asuka
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    ANTICANCER RESEARCH, 2011, 31 (12) : 4519 - 4523
  • [5] The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
    JianWei Zhang
    YuanYuan Zhao
    Ying Guo
    Cong Xue
    ZhiHuang Hu
    Yan Huang
    HongYun Zhao
    Jing Zhang
    Xuan Wu
    WenFeng Fang
    YuXiang Ma
    Li Zhang
    Chinese Journal of Cancer, 2014, 33 (02) : 105 - 114
  • [6] Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 589 - 599
  • [7] First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Wang, Shuyun
    Gao, Aiqin
    Liu, Jie
    Sun, Yuping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) : 443 - 453
  • [8] Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis
    Xiao, Jian
    Zhou, Liang
    He, Bixiu
    Chen, Qiong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs
    Tanaka, Hidenori
    Kimura, Tatsuo
    Kudoh, Shinzoh
    Mitsuoka, Shigeki
    Watanabe, Tetsuya
    Suzumura, Tomohiro
    Tachibana, Keisei
    Noguchi, Masayuki
    Yano, Seiji
    Hirata, Kazuto
    INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (06) : 1410 - 1416
  • [10] Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
    Wang, Yujia
    Wu, Guoyu
    Li, Ru
    Luo, Yingzhe
    Huang, Xingmei
    He, Lifang
    Zhong, Huihui
    Xiong, Shaoquan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9